MX2021003663A - Reprogramacion celular para revertir el envejecimiento y promover la regeneracion de organos y tejidos. - Google Patents
Reprogramacion celular para revertir el envejecimiento y promover la regeneracion de organos y tejidos.Info
- Publication number
- MX2021003663A MX2021003663A MX2021003663A MX2021003663A MX2021003663A MX 2021003663 A MX2021003663 A MX 2021003663A MX 2021003663 A MX2021003663 A MX 2021003663A MX 2021003663 A MX2021003663 A MX 2021003663A MX 2021003663 A MX2021003663 A MX 2021003663A
- Authority
- MX
- Mexico
- Prior art keywords
- combination
- vectors
- engineered
- klf4
- sox2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Marine Sciences & Fisheries (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Abstract
Se proveen en la presente ácidos nucleicos diseñados (por ejemplo, vectores de expresión, incluyendo vectores virales, tales como vectores lentivirales, vectores adenovirales, vectores de AAV, vectores virales de herpes, y vectores retrovirales) que codifican OCT4; KLF4; SOX2; o cualquier combinación de los mismos que es útil, por ejemplo, para inducir la reprogramación celular, la reparación de tejido, la regeneración de tejido, la regeneración de órgano, revertir el envejecimiento, o cualquier combinación de los mismos; también se proveen en la presente virus recombinantes (por ejemplo, lentivirus, alfavirus, virus vaccinia, adenovirus, virus de herpes, retrovirus, o AAVs) que comprenden los ácidos nucleicos diseñados (por ejemplo, ácidos nucleicos diseñados), células diseñadas, composiciones que comprenden los ácidos nucleicos diseñados, los virus recombinantes, células diseñadas, proteínas diseñadas, agentes químicos que son capaces de activar la expresión de OCT4; KLF4; SOX2; o cualquier combinación de los mismos, una proteína diseñada seleccionada del grupo que consiste de OCT4; KLF4; SOX2; o cualquier combinación de las mismas, un anticuerpo 15 capaz de activar la expresión de OCT4; KLF4; SOX2; o cualquier combinación de los mismos, y métodos para tratar una (por ejemplo, enfermedad ocular), prevenir una enfermedad (por ejemplo, enfermedad ocular), regular (por ejemplo, inducir o inducir y luego detener) la reprogramación celular, regular la reparación de tejido, regular la regeneración de tejido, o cualquier combinación de los mismos).
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862738922P | 2018-09-28 | 2018-09-28 | |
US201962792283P | 2019-01-14 | 2019-01-14 | |
US201962865877P | 2019-06-24 | 2019-06-24 | |
US201962880488P | 2019-07-30 | 2019-07-30 | |
PCT/US2019/053545 WO2020069373A1 (en) | 2018-09-28 | 2019-09-27 | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021003663A true MX2021003663A (es) | 2021-05-28 |
Family
ID=68281948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021003663A MX2021003663A (es) | 2018-09-28 | 2019-09-27 | Reprogramacion celular para revertir el envejecimiento y promover la regeneracion de organos y tejidos. |
Country Status (11)
Country | Link |
---|---|
US (2) | US20230048010A1 (es) |
EP (1) | EP3856226A1 (es) |
JP (1) | JP2022511373A (es) |
KR (1) | KR20210068485A (es) |
CN (1) | CN113453702A (es) |
AU (1) | AU2019347666A1 (es) |
BR (1) | BR112021004670A2 (es) |
CA (1) | CA3113472A1 (es) |
IL (1) | IL281470A (es) |
MX (1) | MX2021003663A (es) |
WO (1) | WO2020069373A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110628821B (zh) * | 2018-06-25 | 2022-02-18 | 首都医科大学宣武医院 | 一种细胞模型及其制备方法、应用 |
WO2022217142A1 (en) * | 2021-04-09 | 2022-10-13 | Washington University | Compositions and methods for treatment of crx-linked retinopathies |
CN114240934B (zh) * | 2022-02-21 | 2022-05-10 | 深圳大学 | 一种基于肢端肥大症的图像数据分析方法及系统 |
WO2023192876A1 (en) * | 2022-03-28 | 2023-10-05 | Reilly Steve E | Composition to increase cellular longevity |
CN114622020B (zh) * | 2022-03-30 | 2022-09-27 | 华南农业大学 | 一种与鸡生长性状相关的klhl31基因分子标记及应用 |
WO2023196851A1 (en) | 2022-04-06 | 2023-10-12 | President And Fellows Of Harvard College | Reversing aging of the central nervous system |
WO2023200223A1 (ko) * | 2022-04-15 | 2023-10-19 | 주식회사 로노 | 노화 세포의 회춘 또는 세포 노화의 지연 또는 방지용 조성물 |
WO2024012502A1 (zh) * | 2022-07-12 | 2024-01-18 | 南京瑞初医药有限公司 | 组合物及其使用方法 |
WO2024012504A1 (zh) * | 2022-07-12 | 2024-01-18 | 南京瑞初医药有限公司 | 组合物及其使用方法 |
WO2024012503A1 (zh) * | 2022-07-12 | 2024-01-18 | 南京瑞初医药有限公司 | 组合物及其使用方法 |
WO2024020033A2 (en) * | 2022-07-19 | 2024-01-25 | Syntax Bio, Inc. | Systems for stem cell programming and methods thereof |
WO2024073570A1 (en) * | 2022-09-28 | 2024-04-04 | Altos Labs, Inc. | Expression of regeneration factors in aged/senescent cells |
CN116041477B (zh) * | 2022-10-13 | 2023-08-08 | 呈诺再生医学科技(北京)有限公司 | Tdgf1基因在制备治疗衰老相关疾病或逆转细胞衰老的药物中的应用 |
CN115607689A (zh) * | 2022-10-13 | 2023-01-17 | 呈诺再生医学科技(北京)有限公司 | Klf7基因在制备逆转细胞衰老的药物中的应用 |
CN116970604B (zh) * | 2023-04-24 | 2024-03-08 | 首都儿科研究所 | 一种shRNA、慢病毒载体及其构建方法和应用 |
CN116555432B (zh) * | 2023-07-05 | 2023-09-05 | 广州凯普医药科技有限公司 | 一种膀胱癌快速检测试剂盒 |
CN116898988A (zh) * | 2023-08-15 | 2023-10-20 | 臻赫医药(杭州)有限公司 | 皮肤重编程因子制剂、生物材料及用途 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5651981A (en) | 1994-03-29 | 1997-07-29 | Northwestern University | Cationic phospholipids for transfection |
US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5767099A (en) | 1994-12-09 | 1998-06-16 | Genzyme Corporation | Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
US5851548A (en) | 1995-06-07 | 1998-12-22 | Gen-Probe Incorporated | Liposomes containing cationic lipids and vitamin D |
US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
CA2325088A1 (en) | 2000-12-01 | 2002-06-01 | Fusogenix Inc. | Novel membrane fusion proteins derived from poikilothermic reovirus |
CA2406745C (en) | 2001-11-13 | 2006-01-10 | The Trustees Of The University Of Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
WO2006023207A2 (en) | 2004-08-19 | 2006-03-02 | The United States Of America As Represented By The Secretary Of Health And Human Services, Nih | Coacervate of anionic and cationic polymer forming microparticles for the sustained release of therapeutic agents |
JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
US20100190250A1 (en) * | 2005-10-14 | 2010-07-29 | Jifan Hu | Methods of Rejuvenating Cells In Vitro and In Vivo |
US8278104B2 (en) * | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
US8790664B2 (en) | 2008-09-05 | 2014-07-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Multimodular assembly useful for intracellular delivery |
US8636884B2 (en) | 2008-09-15 | 2014-01-28 | Abbott Diabetes Care Inc. | Cationic polymer based wired enzyme formulations for use in analyte sensors |
US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
US20110142886A1 (en) | 2009-12-01 | 2011-06-16 | Intezyne Technologies, Incorporated | Pegylated polyplexes for polynucleotide delivery |
GB201008267D0 (en) | 2010-05-18 | 2010-06-30 | Univ Edinburgh | Cationic lipids |
DK2575767T3 (en) | 2010-06-04 | 2017-03-13 | Sirna Therapeutics Inc | HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES |
CA2821504C (en) | 2010-09-20 | 2019-03-26 | Spi Pharma, Inc. | Microencapsulation process and product |
US10227386B2 (en) | 2010-09-29 | 2019-03-12 | Entos Pharmaceuticals Inc. | Recombinant polypeptides for membrane fusion and uses thereof |
US20140005269A1 (en) | 2010-11-26 | 2014-01-02 | University Of The Witwatersrand, Johannesburg | Polymeric matrix of polymer-lipid nanoparticles as a pharmaceutical dosage form |
KR101255338B1 (ko) | 2010-12-15 | 2013-04-16 | 포항공과대학교 산학협력단 | 표적 세포에 대한 폴리뉴클레오티드 전달체 |
EP2651400B2 (en) | 2010-12-16 | 2023-01-18 | Amgen (Europe) GmbH | Controlled release oral dosage forms of poorly soluble drugs and uses thereof |
US8709466B2 (en) | 2011-03-31 | 2014-04-29 | International Business Machines Corporation | Cationic polymers for antimicrobial applications and delivery of bioactive materials |
PL2694642T3 (pl) * | 2011-04-08 | 2019-01-31 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Sposób odmładzania komórek |
US10092660B2 (en) | 2011-04-25 | 2018-10-09 | Stc.Unm | Solid compositions for pharmaceutical use |
US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
WO2014053082A1 (en) * | 2012-10-01 | 2014-04-10 | Shih-Hwa Chiou | Method for preparing induced pluripotent stem cells and its applications |
US11339437B2 (en) | 2014-03-10 | 2022-05-24 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
-
2019
- 2019-09-27 MX MX2021003663A patent/MX2021003663A/es unknown
- 2019-09-27 AU AU2019347666A patent/AU2019347666A1/en active Pending
- 2019-09-27 CA CA3113472A patent/CA3113472A1/en active Pending
- 2019-09-27 CN CN201980078793.XA patent/CN113453702A/zh active Pending
- 2019-09-27 EP EP19789835.6A patent/EP3856226A1/en active Pending
- 2019-09-27 BR BR112021004670-4A patent/BR112021004670A2/pt unknown
- 2019-09-27 JP JP2021517602A patent/JP2022511373A/ja active Pending
- 2019-09-27 KR KR1020217012206A patent/KR20210068485A/ko unknown
- 2019-09-27 WO PCT/US2019/053545 patent/WO2020069373A1/en active Application Filing
- 2019-09-27 US US17/280,384 patent/US20230048010A1/en active Pending
-
2021
- 2021-03-14 IL IL281470A patent/IL281470A/en unknown
-
2023
- 2023-05-16 US US18/318,566 patent/US20230338468A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3113472A1 (en) | 2020-04-02 |
AU2019347666A1 (en) | 2021-03-25 |
BR112021004670A2 (pt) | 2021-06-01 |
US20230048010A1 (en) | 2023-02-16 |
WO2020069373A1 (en) | 2020-04-02 |
KR20210068485A (ko) | 2021-06-09 |
CN113453702A (zh) | 2021-09-28 |
US20230338468A1 (en) | 2023-10-26 |
IL281470A (en) | 2021-04-29 |
JP2022511373A (ja) | 2022-01-31 |
EP3856226A1 (en) | 2021-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021003663A (es) | Reprogramacion celular para revertir el envejecimiento y promover la regeneracion de organos y tejidos. | |
EA201791971A1 (ru) | Онколитический аденовирус, кодирующий белок b7 | |
CL2019002474A1 (es) | Vector clado f de virus adeno-asociado (vaa) y usos relacionados. | |
EA202192501A1 (ru) | Рекомбинантные аденоассоциированные вирусные векторы | |
CL2017002199A1 (es) | Vectores retrovirales a lentivirales | |
CL2019003561A1 (es) | Agentes potenciadores para la transfección celular mejorada y/o la producción del vector raav. | |
BR112018008766A2 (pt) | variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos | |
PH12020550117A1 (en) | Variant rnai | |
EA202191418A1 (ru) | Рекомбинантные вирусные векторы и нуклеиновые кислоты для их получения | |
TR201815552T4 (tr) | Agregasyon ile ilgili hastalıkların tedavisine yönelik iyileştirilmiş nanoantikorlar (TM). | |
DE602005026269D1 (de) | Sequenzielle freisetzung immunogener moleküle über adenoviren und adeno-assoziierte viren vermittelte abgaben | |
JP2017505626A5 (es) | ||
WO2020069339A8 (en) | Mutant reverse tetracycline transactivators for expression of genes | |
CA2571318A1 (en) | Nerve regeneration by transplanting cells expressing recombinant transforming growth factor superfamily protein | |
EA202092362A1 (ru) | Вирусные векторы для нацеливания на ткани глаза | |
CO2021016200A2 (es) | Composiciones útiles para el tratamiento de la enfermedad de pompe | |
EP4257155A3 (en) | Compositions and methods for treating wilson's disease | |
CL2021002226A1 (es) | Transactivadores de dominios de unión a adn y usos de estos | |
PE20230433A1 (es) | Composiciones de virus adenoasociados para restaurar la funcion del gen pah y los metodos de uso de estas | |
BR112022021918A2 (pt) | Composições e métodos para o tratamento de fibrose cística | |
DK0817858T3 (da) | Vektorer, som indeholder terapeutiske gener for antimikrobielle peptider, til anvendelse ved genterapi | |
BR112021024855A2 (pt) | Composições de vírus adenoassociados para transferência de gene arsa e métodos de uso das mesmas | |
WO2022035962A3 (en) | Proteins, polynucleotides, and methods for treating coronavirus infection | |
BR112018006820A2 (pt) | anticorpos anti-psa (5a10) humanizados | |
BR112023018430A2 (pt) | Terapias gênicas para deficiência de 21-hidroxilase |